Drugs / BL-M08D1
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06718621 | Feb 2025 → Dec 2026 expected | cancer | Sichuan Baili Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1 | NCT06718634 | Jan 2025 → Jun 2027 expected | lymphoma | Sichuan Baili Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2026-06-05 | Sichuan Biokin Pharmaceutical Co., Ltd. | Regulatory 四川百利天恒药业股份有限公司自愿披露关于注射用BL-M08D1(ADC)联合用药治疗弥漫大B细胞淋巴瘤获得药物临床试验批准通知书的公告 cninfo.com.cn ↗ |
| 2024-11-29 | Sichuan Biokin Pharmaceutical Co., Ltd. | Regulatory 四川百利天恒药业股份有限公司自愿披露关于注射用BL-M08D1（ADC）项目治疗复发或难治性血液系统恶性肿瘤和局部晚期或转移性实体瘤获得药物临床试验批准通知书的公告 cninfo.com.cn ↗ |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-06-05 | Sichuan Biokin Pharmaceutical Co., Ltd. | 四川百利天恒药业股份有限公司自愿披露关于注射用BL-M08D1(ADC)联合用药治疗弥漫大B细胞淋巴瘤获得药物临床试验批准通知书的公告 cninfo.com.cn ↗ |
| 2024-11-29 | Sichuan Biokin Pharmaceutical Co., Ltd. | 四川百利天恒药业股份有限公司自愿披露关于注射用BL-M08D1（ADC）项目治疗复发或难治性血液系统恶性肿瘤和局部晚期或转移性实体瘤获得药物临床试验批准通知书的公告 cninfo.com.cn ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BL-M08D1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06718621 ↗ |
| Route | Intravenous | “Administration by intravenous infusion for a cycle of 3 weeks.” NCT06718621 ↗ |